Navigation Links
Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Date:2/1/2008

ALLEGAN, Mich., Feb. 1 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) today announced that the Board of Directors has authorized the repurchase of $150 million of the Company's common stock through February 1, 2010 under its ongoing share repurchase program. Any remaining balance of the previously authorized program will expire on February 8, 2009. Under share repurchase programs since November 2000, Perrigo has repurchased 11.4 million shares at a cost of approximately $174 million. As of January 25, 2008, Perrigo had 93,080,386 common shares outstanding.

The Company also announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on March 18, 2008 to shareholders of record on February 22, 2008.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).


'/>"/>
SOURCE The Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2009)...recognize signs of depression , , SATURD...the holiday season can trigger melancholy as they ...issues or worry about money problems, according to...rcome the seasonal blues, the AGS Foundation for H...t out and socialize or invite family and friends o...
(Date:11/27/2009)...wire-FirstCall/ -- The Gymboree Corporation (Nasda...will present at the NASDAQ OMX 23rd Investor Progr...ndon, England, on Wednesday, December 2, 2009, at ...t of The Gymboree Corporation,s presentation over ...lick on "Our Company" at the bottom of the page, g...
(Date:11/27/2009)...icles may reduce future disease burden, researcher...s) -- Encouraging city dwellers to walk and bicycl...ublic health benefits than increased used of low-e..., The study compared the projected health effects ...ios for London, England, and Delhi, India: busine...
(Date:11/27/2009)...facturers who use medical load cells at the heart ...y bringing in technology partner Flintec early in ...ve medical manufacturers are calling in Flintec lo...ects, ensuring that progress will not be constrain...dated technology. , (PRWE...
(Date:11/26/2009)...olybdate (TM) has been shown in studies to be effe...e caused by an overload of copper, and certain met...however, is known about how the drug works at the ...rn University researchers now has provided an inva... bound to copper-loaded metallochaperones. The dru...
Breaking Medicine News(10 mins):Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3
..., Dec. 3, 2008 Joined by actress Maggie,Gyllenhaa...tionwide search for,five child Holiday Ambassadors...an event in New York City. The Duracell Holiday A...spread the joy of powering,up a gift for the first...
...., Dec. 3 Decision Resources, one of the,world,s ...armaceutical and,healthcare issues, finds that the...se in China is extremely low and will remain low t...eimer,s disease,population in China in 2012, less ...
... NextAdvisor.com has created a free g...ch to dieting. , San Fran....com , the trusted, independent source for compari...useful advice for those embarking on a new diet pl...
... Around 80 HBA, MBF and Mutual Commun...ir feet where their mouths were on Sunday to promo... charity in the inaugural HBA Great Australian Run... put their feet where their mouths were on Sunday ...
...Dec. 3 AGA Medical Corporation announced,today th...enne) approval for,its AMPLATZER(R) Cardiac Plug (...vasive solution for closing cardiac structures not...t addition to the interventional tools we have for...
...ec. 3, 2008 Scientists at UT Southwestern Medical...tein interferon plays a key role in "teaching" the...s of the same virus. , The findings, available on...therapies. , Typically, when a person is infecte...
Other Medicine News:Health News:Duracell and Actress Maggie Gyllenhaal Announce Winners of 'Power A Smile' Casting Call After Nationwide Search for Five Child Holiday Ambassadors 2Health News:Duracell and Actress Maggie Gyllenhaal Announce Winners of 'Power A Smile' Casting Call After Nationwide Search for Five Child Holiday Ambassadors 3Health News:Diagnosis and Drug Treatment of Alzheimer's Disease in China is Low and Will Remain Low Through 2012 2Health News:Diagnosis and Drug Treatment of Alzheimer's Disease in China is Low and Will Remain Low Through 2012 3Health News:NextAdvisor.com Launches "Lose the Weight this Year: A Common Sense Dieter's Guide" 2Health News:HBA People Walk the Talk for Better Health in the HBA Great Australian Run 2Health News:AGA Medical Receives European CE Mark Approval for AMPLATZER(R) Cardiac Plug 2Health News:Interferon needed for cells to 'remember' how to defeat a virus, UT Southwestern researchers report 2
(Date:11/25/2009)... 25 Cempra Pharmaceuticals Inc. to...t and chief executive officer, will present at the...at 8:50 a.m. EST, December 1, 2009, at The New Yor...ll provide an overview of the company,s two leadin...f drug-resistant pathogens including MRSA. ,, ...
(Date:11/25/2009)...25 ChemoCentryx, Inc., announced...mpany,s PROTECT-1 (the Prospective Randomized Oral...raficet-EN(TM) (CCX282-B) in patients with moderat...efficacy with a favorable safety and tolerability ...cal efficacy in the reduction of disease severity ...
(Date:11/24/2009)...RNewswire-FirstCall/ -- Vermillion, Inc. (VRML) (P... Plan of Reorganization and Disclosure Statement t...nkruptcy Court for the District of Delaware. A hea...ent is presently scheduled for December 8, 2009, w...heduled for January 7, 2010. ,, The Plan calls...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Vermillion Files Plan of Reorganization 4ViroPharma Receives Complete Response Letter for Cinryze 28TM 29 Supplemental Biologics License Application for Acute Treatment of Hereditary Angioede 12463 1ViroPharma Receives Complete Response Letter for Cinryze 28TM 29 Supplemental Biologics License Application for Acute Treatment of Hereditary Angioede 12463 2ViroPharma Receives Complete Response Letter for Cinryze 28TM 29 Supplemental Biologics License Application for Acute Treatment of Hereditary Angioede 12463 3ViroPharma Receives Complete Response Letter for Cinryze 28TM 29 Supplemental Biologics License Application for Acute Treatment of Hereditary Angioede 12463 4ViroPharma Receives Complete Response Letter for Cinryze 28TM 29 Supplemental Biologics License Application for Acute Treatment of Hereditary Angioede 12463 5EUCODIS Bioscience Launches Beta Lactamase for Antibiotics and Diagnostics Industries 12462 1EUCODIS Bioscience Launches Beta Lactamase for Antibiotics and Diagnostics Industries 12462 2Cardiac Science to Present at Needham Biotechnology 26 Medical Technology Conference 47874 1Cardiac Science to Present at Needham Biotechnology 26 Medical Technology Conference 47874 2Cardiac Science to Present at Needham Biotechnology 26 Medical Technology Conference 47874 3
... Congresswoman Debbie,Wasserman Schultz will prese... the U.S. Department of Defense to support spinal ...y Professor Jeffery Alan Plunkett - a leader in,sp...ity President Monsignor,Franklyn M. Casale will pr...cience programs - including financial aid opportun...
... 21 Qualia Clinical Services, a highly,regarded d...Logos,Technologies electronic data capture (EDC) s...n its Phase I clinical facility in Omaha,Nebraska....ity with ALPHADAS will,enable us to provide our Ph...ime access to critical data while conducting state...
Other Medicine Technology:Qualia Clinical Services Chooses ALPHADAS(R) for Phase I Clinical Trials 2
DErrico Perforator Drill and Enlarging Burr
Cushing Perforator Drill
Doro J-Arm Retractor System
Spoon End Periosteal
Medicine Products: